United Kingdom Anti-Rheumatic Drug Market - Strategic Insights and Forecasts (2022-2027)

The United Kingdom's anti-rheumatic drug market was valued at US$4.33 billion in 2020. It is projected to grow at a Compound Annual Growth Rate (CAGR) of 3.93%, reaching an estimated value of US$5.66 billion by 2027.

The market's growth is primarily driven by the high prevalence of rheumatic diseases, with over 10 million people in the UK suffering from arthritis and related conditions. Additionally, a world-class healthcare sector, growing healthcare expenditure enabling access to costly treatments, and an increasing geriatric population contribute significantly to market expansion.

The report segments the market based on the type of disease, including Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, and others. Further segmentation covers molecule types such as pharmaceuticals and biopharmaceuticals, and sales channels, distinguishing between prescription and over-the-counter (OTC) drugs.

The COVID-19 pandemic initially had a negative impact on the UK anti-rheumatic drug market. However, certain DMARDs and biologics routinely used for rheumatoid arthritis, such as hydroxychloroquine, sarilumab, tocilizumab, and anakinra, were studied as potential COVID-19 treatments, which subsequently boosted growth prospects for manufacturers of these specific medications during the anticipated period.

The growing number of people aged 65 and above in the United Kingdom directly correlates with a rise in age-associated conditions like joint pain, back pain, and rheumatoid arthritis. This demographic shift necessitates increased demand for various anti-rheumatic drugs for disease treatment, thereby significantly driving market growth.

The report provides insights into key growth opportunities stemming from the high prevalence of rheumatic diseases and the robust healthcare infrastructure. It highlights the strategic importance of growing healthcare expenditure and demographic shifts, such as the increasing geriatric population, in shaping future market demand and potential for drug innovation across different molecule types and sales channels.